News | October 27, 2021
Cipla consolidated net profit at Rs 711.36 cr. in Q2FY22
Cipla has reported consolidated financial results for the period ended September 30, 2021
Cipla has reported consolidated financial results for the period ended September 30, 2021
FDI increased 98% year on year in 2020 and pharma exports grew by 18% in the last financial year
Filing marks first protein-based vaccine submitted to MHRA for authorization
Support from DFC will help produce one billion vaccine doses by the end of 2022
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan
Subscribe To Our Newsletter & Stay Updated
